Two high-growth mid-cap stocks to add to your watch list

Double-digit earnings growth, healthy balance sheets and high future potential have me watching these companies closely.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing in the pharmaceutical industry can be a bit of a hit or miss exercise for retailer investors. While companies in the sector can enjoy sky-high margins and years of protected revenue thanks to patents, their share prices can also fluctuate wildly based on poor clinical trial results or a rival gazumping them with a new competitor drug.

That’s why I’ve got my eye on £2bn market cap UDG Healthcare (LSE: UDG), a provider of marketing, sales and packaging services for pharmaceutical firms. The company is exposed to the upside of rising global use of pharmaceutical products, as well as the trend among pharma firms to outsource non-core operations such as training local sales teams or educating healthcare professionals on how best to use their drugs.

This is where UDG shines and as it proves its worth with existing clients and expands the array of services it offers and moves into new countries, it’s bringing in ever larger partners. This is paying off with sales for the half year to March rising 15% year-on-year (y/y) in constant currency terms to $578.9m, and pre-tax profits leaping a full 29% during the period to $52.9m.

This impressive performance has continued into Q3 with good trading and new acquisitions leading management to raise its earnings per share guidance to between 17% to 19% ahead of last year’s 31.8 US cents. The bad news is that taking the midpoint of this estimate would give UDG a valuation of around 28.9 times full year earnings.

While I see plenty of reasons to believe UDG will continue to grow organically and through acquisitions, improve its margins and maintain a healthy balance sheet, this valuation is simply too stretched compared to historic averages to make me comfortable. However, I will be keeping a close eye on the company and wait patiently for a more reasonable valuation before considering beginning a position.

Electric growth potential 

Another mid-cap for which I’m awaiting a share price dip is the aptly named electronics components distributor Electrocomponents (LSE: ECM). The company serves as a middle-man between manufacturers and end users in industries ranging from utilities, to miners, electronics and manufacturers of all stripes.

The company’s growth is down to plain old macroeconomic growth across the globe as well as increasing consolidation in the sector that favours large players such as itself. Last year underlying sales grew 4.8% y/y and 17.1% in reported currency terms to £1,511m, while operating margins rose 240 basis points to 8.8% and boosted operating profit to £133m.

In the quarter to June, this growth has picked up as each of its three main trading regions, North America, Europe and Asia, grew revenue by at least 10% y/y. The combination of continued economic growth in each of these regions, small bolt-on acquisitions and increased investment in sales staff training bodes well for this growth continuing for some time to come.

Furthermore, with a highly cash generative business that produced free cash flow of £117m last year and net debt less than one times EBITDA, there’s plenty of potential for both future acquisitions and increased shareholder returns. I like Electrocomponents a lot, but its valuation of 25 times forward earnings is just a bit too expensive for my taste.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »